linjc16/ctgov huggingface dataset:
Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
Periodontitis is a chronic disease of the supporting tissue of the teeth, characterized by bleeding and inflamed gingival, resorption of alveolar bone. This disease has a significant impact of the quality of life as the teeth become progressively mobile and may fall out spontaneously if no treatment is provided. Periodontal disease has been cited as the sixth complication of diabetes mellitus.Chromogranins / secretogranins are a family of proteins present in nervous endocrine and immune cells, released with catecholamines during stress situations. Chromogranin A (CGA) is the major member of this family.The aim of this study is to determine the level of CGA and its derived peptides in the gingival crevicular fluid (GCF) of health or diabetic patients with and without periodontitis.Then, we want to determine the antimicrobial activity of these peptides.

Official Title
-----------------
Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis

Conditions
-----------------
Periodontitis and Diabetitis

Intervention / Treatment
-----------------
* Procedure: Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients from 20 to 80 years old A minimum of 10 teeth Healthy volunteers or diabetic patients with or without periodontitis Exclusion criteria: a course of antibiotics a fungicidal therapy a corticotherapy a hormone therapy a pregnancy persons under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Periodontitis, Diabetes, Gingival crevicular fluid, GCF, Saliva, Chromogranin, Electrophorèse, Western Blot, RT-HPLC
Bacterial Infections in Patients With Cirrhosis in Argentina: Clinical and Microbiological Characteristics

Study Overview
=================
Brief Summary
-----------------
In recent years, there has been an increasing prevalence of bacterial infections caused by multiresistant and extremely resistant organisms in patients with cirrhosis. These infections are associated with a worse prognosis, generate difficulties in the management of the patient during hospitalization and increase health costs. The main objective of this project is to estimate the prevalence of infections by multiresistant bacteria in patients with cirrhosis. Additionally, the prevalence of other antibiotic resistance patterns and morbi-mortality in the study population will be evaluated. For these purposes, a multicenter prospective cohort study will be carried out, including patients with cirrhosis who present bacterial infections at the time of admission, or during hospitalization. Performing a study in Argentina on the clinical and microbiological characteristics of bacterial infections in patients with cirrhosis could be very useful to develop new strategies for prevention and treatment of this severe complication.

Official Title
-----------------
Bacterial Infections in Patients With Cirrhosis in Argentina

Conditions
-----------------
Bacterial Infections, Cirrhosis, Resistant Infection, Morality

Intervention / Treatment
-----------------
* Other: This is an observational study without intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with cirrhosis Patients older than 17 years. Patients who are hospitalized for bacterial infections, or who develop bacterial infections while hospitalized Exclusion Criteria: • Refusal to participate in the informed consent process

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: This is an observational study without intervention|This is an observational study without intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To estimate the prevalence of infections caused by multi-resistant microorganisms in patients with cirrhosis |  | at the moment of the diagnosis of the bacerial infection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate variables associated with infections caused by multi-resistant microorganisms in patients with cirrhosis |  | at the moment of the diagnosis of the bacerial infection | 
| To evaluate the effect of infections caused by multi-resistant microorganisms on the in-hospital survival of patients with cirrhosis |  | 30 days |
Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

Study Overview
=================
Brief Summary
-----------------
The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Detailed Description
-----------------
Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.

Official Title
-----------------
Effectiveness of Matrix Metalloproteinase Neutralizing Agent in Treatment of Oral Lichen Planus: A Pilot Study

Conditions
-----------------
Oral Lichen Planus

Intervention / Treatment
-----------------
* Drug: Matrix Metalloproteinase Inhibitors (Orochem)
* Drug: Kenacort A,


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with erosive OLP confirmed with a biopsy. patients should have symptomatic lesions Exclusion Criteria: Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: double equal arms
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Orochem (Test)<br>fifteen patients with lichen planus will be treated with MMPs neutralizing agent 3 times daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods. | Drug: Matrix Metalloproteinase Inhibitors (Orochem)<br>* topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus<br>|
| Active Comparator: Conventional (Control)<br>fifteen patients with oral lichen planus confirmed with a biopsy will be treated with topical corticosteroids, topical antifungal 3 timed daily for 3 weeks. then pain, discomfort and disease severity will be assessed at 1 and 3 weeks periods. | Drug: Kenacort A,<br>* topical application of both drugs 3 times daily for 3 weeks as an active control<br>* Other names: miconaz gel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in disease severity score | Thongprasom disease severity score (5-0) | change in disease severity score from baseline to 3 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
matrix metalloproteinase inhibitors, orochem, OLP
The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application

Study Overview
=================
Brief Summary
-----------------
Patients undergoing major surgery, trauma and burns are prone to develop an exacerbated inflammatory response, which is potentially lethal to the individual. Recently our group demonstrated that administration of high fat feeding prior to hemorrhagic shock attenuates severe inflammation, gut barrier loss and hepatic damage. High fat feeding releases cholecystokinin in the gut, which stimulates the autonomous nervous system and subsequently activates the efferent vagus nerve. The activated efferent fibers inhibit tissue macrophages via binding of acetylcholine to the alpha7-nicotinergic receptor. In this study the cholecystokinin release in healthy volunteers is monitored in response to low fat and high fat food products.

Official Title
-----------------
The Anti-inflammatory Effects of High-fat Nutrition; Towards a Clinical Application

Conditions
-----------------
Trauma

Intervention / Treatment
-----------------
* Dietary Supplement: nutritional intervention with Respifor and Diasip


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males and females 45 > age <55 Exclusion Criteria: Gastrointestinal diseases Inflammatory conditions

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CCK-release |  | two hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CCK release
Effect of Structured Patient Interviews in the Preoperative Anesthesia Clinic on Recall of Relevant Information

Study Overview
=================
Brief Summary
-----------------
The preanesthetic visit influences patient satisfaction and medical outcome. This study aims to evaluate whether training for a structured interview technique improves communication skills, resulting in increased recall of relevant information by surgical patients.

Official Title
-----------------
Effect of Structured Patient Interviews in the Preoperative Anesthesia Clinic on Recall of Relevant Information

Conditions
-----------------
Anesthesia, Surgical Procedure, Unspecified, Communication

Intervention / Treatment
-----------------
* Other: Trained anesthesiogist


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Surgical patients in the preoperative anesthesia clinic Written informed consent Exclusion Criteria: Inadequate comprehension of the German language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Trained anesthesiologist<br>Patient interview by anesthesiologists having obtained training to optimize structured communication | Other: Trained anesthesiogist<br> <br> |
| No Intervention: Control anesthesiologist<br>Patient interview by control anesthesiologists | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recall of information | Number of recalled information items in free text, expert assessment according to predefined Delphi criteria | Immediately after patient interview |
COMPASSION S3 Post-Approval Study

Study Overview
=================
Brief Summary
-----------------
This study will monitor device performance and outcomes of the SAPIEN 3 Transcatheter Heart Valve (THV) System in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention.

Detailed Description
-----------------
This is a single arm, prospective, multicenter post-approval study.

Official Title
-----------------
Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV Post-Approval Study

Conditions
-----------------
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration, Pulmonary Valve; Obstruction

Intervention / Treatment
-----------------
* Device: SAPIEN 3 THV


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dysfunctional RVOT conduit or previously implanted surgical valve RVOT/PV with ≥ moderate regurgitation and/or a mean RVOT/PV gradient of ≥ 35 mmHg Exclusion Criteria: Inability to tolerate an anticoagulation/antiplatelet regimen Active bacterial endocarditis or other active infections
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TPVR<br>Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR). | Device: SAPIEN 3 THV<br>* SAPIEN 3 THV in the pulmonic position<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device Success | Defined as a composite of: Single THV implanted in the desired location Right ventricle to pulmonary artery peak-to-peak gradient < 35 mmHg post-implantation Less than moderate PR by discharge TTE Free of explant at 24 hours post-implantation | Discharge, expected to be within 1-5 days post-procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transcatheter pulmonary valve replacement, Transcatheter pulmonary valve implantation, SAPIEN 3
Articaine Efficacy and Safety for Children Below Age of 4-years

Study Overview
=================
Brief Summary
-----------------
Pain control is one of the significant behavior determinants in the dental office and shaping the future attitude toward dentistry, especially in children. One of widely used local anesthetic agents is articaine hydrochloride because of its superior potency, over traditionally used 2% lidocaine. Therefore, this study intends to get the benefits of articaine efficiency and apply it in children.

Official Title
-----------------
Articaine Efficacy and Safety in Young Children Below Age of Four Years: An Equivalent Parallel Randomized Control Trial

Conditions
-----------------
Behaviour Assessment, Pain

Intervention / Treatment
-----------------
* Drug: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml
* Drug: lidocaine hydrochloride 2% and epinephrine 1:100000


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 36-47 months. ASA I, II. Mentally capable of communication. Having a mandibular primary molar tooth that required extraction or pulpotomy. Exclusion Criteria: The presence of infection, which may compromise the efficiency of local anesthetic agent Significant behaviour problems Medical or mental unfitness

Ages Eligible for Study
-----------------
Minimum Age: 37 Months
Maximum Age: 47 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Lidocaine 2% group<br>lidocaine hydrochloride 2% and epinephrine 1:100000 (Lignospan® standard, 1.7ml, SEPTODONT Ltd) | Drug: lidocaine hydrochloride 2% and epinephrine 1:100000<br>* Local anesthetic agent<br>|
| Experimental: Articaine 4%<br>articaine hydrochloride 4% and epinephrine 1:100000 (Septocaine® 1.7ml, SEPTODONT Ltd) | Drug: Articaine 4%/Epi 1:100000 Inj Cart 1.7Ml<br>* Local anesthetic agent<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessment | FLACC scale | During the procedures | 
| Behavior | Frankl behaviour scale | before and after the procedures | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative complications | Asking parents/caregiver in the next 24 hours using Parents' postoperative pain measure (PPPM) | 24 hours after the procedures | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Articaine, local anaesthesia, child, pain
Heated Breathing Circuit on Postoperative Sore Throat After Double-lumen Endobronchial Tube Insertion

Study Overview
=================
Brief Summary
-----------------
This investigation is planned to compare the incidence and severity of postoperative sore throat according to the use of heated breathing circuit in patients undergoing double-lumen endotracheal intubation.

Official Title
-----------------
Influence of Heated Breathing Circuit on Postoperative Sore Throat in Patients Undergoing Double-lumen Endobronchial Tube Insertion

Conditions
-----------------
Lung Surgery

Intervention / Treatment
-----------------
* Device: Heated breathing circuit on
* Device: Heated breathing circuit off


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III Patients scheduled for double-lumen endotracheal intubation Exclusion Criteria: Difficult airway Mallampatti scores greater than 2 Recent sore throat Cervical spine disease Recent upper respiratory infection Recent analgesics History of head and neck surgery Friable teeth Multiple intubation attempts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Control<br>Heated breathing circuit will be turned off. | Device: Heated breathing circuit off<br>* Heated breathing circuit will be turned off.<br>|
| Experimental: Heat<br>Heated breathing circuit will be turned on. | Device: Heated breathing circuit on<br>* Heated breathing circuit will be turned on.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with postoperative sore throat for postoperative 24 h |  | At 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with postoperative sore throat |  | At 1, 6, and 24 hours | 
| Postoperative sore throat scores |  | At 1, 6, and 24 hours | 
| Number of participants with postoperative hoarseness |  | At 1, 6, and 24 hours | 
| Number of participants with postoperative shivering |  | At 1, 6, and 24 hours | 
| Wound pain scores | Visual anlogue scales will be used (10: most imaginable pain, 0: no pain). | At 1, 6, and 24 hours | 
| Jaw discomfort scores | Visual anlogue scales will be used (10: most imaginable pain, 0: no pain). | At 1, 6, and 24 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intubation, pharyngitis